188Re-ZHER2:V2, a promising affibody-based targeting agent against HER2-expressing tumors: preclinical assessment.
Altai M, Wållberg H, Honarvar H, Strand J, Orlova A, Varasteh Z, Sandström M, Löfblom J, Larsson E, Strand SE, Lubberink M, Ståhl S, Tolmachev V.
Altai M, et al. Among authors: strand se, strand j.
J Nucl Med. 2014 Nov;55(11):1842-8. doi: 10.2967/jnumed.114.140194. Epub 2014 Oct 2.
J Nucl Med. 2014.
PMID: 25278516
Free article.